Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer
- 405 Downloads
Preoperative wait time is affected by various factors, and a certain time is needed before surgery. There is a concern that cancer treatment delay can lead to poor survival. The present study aimed to evaluate the impact of preoperative wait time on survival in patients with clinical stage (cStage) II/III gastric cancer.
The study included patients with cStage II/III primary gastric cancer undergoing surgery between 2002 and 2012. Preoperative wait time was defined as the time from endoscopy for initial diagnosis to surgery. Patients were divided into the following three groups according to wait time: short wait group (≤ 30 days), intermediate wait group (> 30 and ≤ 60 days), and long wait group (> 60 and ≤ 90 days). Patient characteristics and survival were compared among the groups.
This study included 467 male (67%) and 229 female (33%) patients, and the median patient age was 67 years. The numbers of cStage II and III patients were 332 (48%) and 364 (52%), respectively. The median wait time was 45 days. The body mass index was lower in the short wait group than in the other groups. A shorter wait time tended to be associated with a more advanced cStage. Although survival was significantly worse in the short wait group than in the long wait group, wait time was not identified as an independent prognostic factor in multivariate analysis.
Preoperative wait time up to 90 days does not affect survival in patients with cStage II/III gastric cancer.
KeywordsGastric cancer Preoperative wait time Surgery Survival
This study was funded by National Cancer Center Research and Development Fund (29-4-3).
Compliance with ethical standards
All procedures followed were in accordance with the ethical standards of responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or an appropriate substitute was obtained.
Conflict of interest
Author MT has received research grants from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical company, Eli Lilly Japan, Ono Pharmaceutical company, Bristol Myers Squib Japan, and Yakult Honsha Co., Ltd. Author EB has received research grants from EIZO Corporation, Kanehara-Shuppan, TERUMO CORPORATION, and EIZAI.
- 1.Cancer Research UK. Cancer waiting times. https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/access-to-treatment/waiting-times-after-diagnosis.